Founded in 2025, Lucis offers a preventive health platform that analyses more than 110 blood biomarkers and combines those results with longitudinal data and physician-reviewed AI insights to deliver personalised nutrition, supplementation, lifestyle, and follow-up testing recommendations. The company has grown rapidly to over 10,000 users across France, the UK, Ireland, and Portugal and has delivered more than one million biomarker tests. Early outcome data shows that among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication, and more than 80% opted to retest; at initial testing 99.9% had at least one biomarker outside optimal ranges. Lucis operates with a team of about 20 employees, a medical board and a network of 10+ physicians providing clinical oversight. The company plans to expand into Spain, Germany, and Italy by the end of 2026 while continuing to invest in personalisation, longitudinal monitoring, and clinical safety.

Total raised

$29M

Funding rounds

2

Latest round

Series A

Latest activity

May 2026